| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | 0.0022 | 0.9 |
| mRNA | Irinotecan | FIMM | pan-cancer | AAC | 0.0072 | 0.9 |